
A conversation with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, clinical assistant professor and director of experiential learning at West Virginia University School of Pharmacy, at AAP 2025.

A conversation with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, clinical assistant professor and director of experiential learning at West Virginia University School of Pharmacy, at AAP 2025.

Awards Honor Excellence and Improvement in Overall CMS Medicare Part D Star Ratings and PQA Medication Measures.

Through communication and reform, pharmacies will be able to make changes in order to continue to provide the best care to patients.

Through digital innovations, transparency, and accessibility, pharmacists can help meet patients where they are at to improve their health outcomes.

A conversation with Greg Mitchell, owner of United Drug Superstore in Hatch, New Mexico, at AAP 2025.

Researchers conducted a review of adherence behaviors for patients with dermatological diseases and provided an update on management strategies.

Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.

From medication dispensers to comprehensive patient care advocates, pharmacists have never been more essential to the health care team and to patients in specialty care.

Results are from an open-label extension of a phase 3 trial assessing the pharmacokinetics, efficacy, safety, and immunogenicity of adalimumab-aaty and its reference formulation Humira.

The role of the community pharmacist is beginning to expand into specialty pharmacy spaces to increase access and outcomes for patients.

Researchers explored the confidence, barriers, and role of general practice independent pharmacists regarding prescribing services within primary care settings.

A conversation with Katherine Tromp, PharmD, interim dean at Northeast Ohio Medical University College of Pharmacy.

Researchers identified differences in naloxone training, policies, procedures, and preferences among chain or independent pharmacies across Alabama.

A discussion with Douglas Hoey, RPh, MBA, CEO of NCPA, at AAP 2025.

The findings support the need for improved vaccination coverage to prevent the resurgence of previously eliminated infectious diseases in the United States.

However, the results show that there was an improvement of symptom scores, although they were not significant.

In a new survey, approximately one-third of respondents have heard that the MMR vaccine is more dangerous than being infected with the infection.

Researchers explored whether or not hormonal contraceptive initiation is associated with increased risk of developing depression within 12 months of child delivery.

Investigators specifically analyze information on influenza and pneumococcal vaccinations.

This method supports improved, early detection for diabetes without relying on blood samples or complex procedures.

CVS releases a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.

Researchers conducted an observational cost analysis of dermatology drug savings between GoodRx and Mark Cuban Cost Plus Drug Company.

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

Researchers explore trends from 2014 to 2022 among pediatric invasive pneumococcal diseases since introduction of the 13-valent pneumococcal conjugate vaccine.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

From 1990 to 2021, researchers explored the global burden of atopic dermatitis among older adults.

Crystal Hodge discusses being transparent about adverse effects of the MMR vaccine and educating patients about measles.

The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.